FY2026 EPS Estimate for SCYNEXIS Cut by Analyst

SCYNEXIS, Inc. (NASDAQ:SCYX) – Analysts at Brookline Capital Markets reduced their FY2026 EPS estimates for SCYNEXIS in a research note issued to investors on Thursday, November 5th. Brookline Capital Markets analyst K. Dolliver now anticipates that the company will post earnings per share of ($3.48) for the year, down from their previous forecast of ($1.60). Brookline Capital Markets currently has a “Buy” rating on the stock. The consensus estimate for SCYNEXIS’s current full-year earnings is ($1.60) per share. Brookline Capital Markets also issued estimates for SCYNEXIS’s Q4 2026 earnings at ($0.43) EPS, Q1 2027 earnings at ($0.38) EPS, Q2 2027 earnings at ($0.38) EPS, Q3 2027 earnings at ($0.38) EPS, Q4 2027 earnings at $0.76 EPS, FY2027 earnings at ($0.37) EPS, FY2028 earnings at ($0.83) EPS, FY2029 earnings at ($4.55) EPS and FY2030 earnings at ($6.20) EPS.

Several other equities analysts have also recently issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of SCYNEXIS in a research note on Thursday, October 22nd. Wall Street Zen lowered shares of SCYNEXIS from a “hold” rating to a “sell” rating in a research note on Saturday. Finally, Guggenheim reissued a “buy” rating and set a $33.00 price objective (up from $24.00) on shares of SCYNEXIS in a report on Thursday, August 13th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $33.00.

SCYNEXIS Stock Performance

NASDAQ SCYX opened at $3.50 on Tuesday. SCYNEXIS has a one year low of $3.28 and a one year high of $9.12. The stock has a 50-day moving average of $4.36 and a 200 day moving average of $5.47. The company has a market capitalization of $34.83 million, a price-to-earnings ratio of -2.43 and a beta of 1.15.

SCYNEXIS (NASDAQ:SCYX) last posted its quarterly earnings results on Thursday, November 5th. The company reported ($0.71) earnings per share for the quarter, topping the consensus estimate of ($0.72) by $0.01. The business had revenue of $0.13 million during the quarter, compared to analysts’ expectations of $0.13 million.

Institutional Investors Weigh In On SCYNEXIS

A number of large investors have recently made changes to their positions in SCYX. Renaissance Technologies LLC lifted its stake in shares of SCYNEXIS by 27.6% in the 1st quarter. Renaissance Technologies LLC now owns 224,640 shares of the company’s stock worth $206,000 after purchasing an additional 48,640 shares during the period. Empery Asset Management LP purchased a new position in shares of SCYNEXIS in the second quarter worth approximately $514,656. ADAR1 Capital Management LLC bought a new stake in SCYNEXIS during the second quarter valued at approximately $201,000. BlackRock Inc. bought a new stake in SCYNEXIS during the second quarter valued at approximately $169,000. Finally, Velan Capital Investment Management LP bought a new stake in SCYNEXIS during the second quarter valued at approximately $163,000. 54.37% of the stock is currently owned by institutional investors.

Key Stories Impacting SCYNEXIS

Here are the key news stories impacting SCYNEXIS this week:

• Positive Sentiment: Brookline Capital Markets kept its Buy rating and raised its FY2027 EPS forecast to a loss of $0.37 from a loss of $0.80, while projecting $0.76 EPS in Q4 2027. That more optimistic 2027 estimate may offer some support to sentiment.
• Positive Sentiment: SCYNEXIS is targeting year-end for a kidney-drug trial, while its antifungal program advances. The article headline signals potential development milestones, though it provides no trial results. SCYNEXIS Targets Year-End Kidney Drug Trial as Antifungal Program Advances
• Negative Sentiment: Brookline cut its FY2026 EPS estimate to a loss of $3.48 from a loss of $1.60 and lowered its Q4 2026 forecast to a loss of $0.43 from a loss of $0.24. It also reduced FY2028 and FY2029 estimates, suggesting weaker expectations in several periods despite its Buy rating.
• Negative Sentiment: Wall Street Zen downgraded SCYNEXIS to Sell, adding a bearish analyst view. SCYNEXIS (NASDAQ:SCYX) Cut to Sell at Wall Street Zen

About SCYNEXIS

SCYNEXIS, Inc is a biotechnology company focused on developing and commercializing innovative antifungal therapies for the treatment of serious and common fungal infections. The company’s research platform is centered on ibrexafungerp, a novel triterpenoid antifungal designed to inhibit glucan synthase, an enzyme important to the formation of fungal cell walls.

SCYNEXIS’s lead product, BREXAFEMME (ibrexafungerp tablets), is an oral antifungal approved in the United States for the treatment of vaginal yeast infections, also known as vulvovaginal candidiasis.